Roche has recently entered into a groundbreaking multi-year collaboration with Oxford BioTherapeutics (OBT), valued at over a billion dollars, to spearhead the development of novel antibody-based cancer treatments. This significant partnership focuses on the creation of innovative therapies such as
Schrödinger, a well-established player in the computational chemistry and drug discovery space, has recently made headlines by embracing artificial intelligence (AI). The company’s CEO, Ramy Farid, officially announced this strategic pivot during the presentation of the company's year-end re
The pharmaceutical landscape is rapidly evolving, and at the forefront of these advancements is Merck & Co.'s groundbreaking licensing agreement with Jiangsu Hengrui Pharmaceuticals, focusing on the innovative Lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This monumental $2 billion deal puts
Google has long been at the forefront of technological innovation, and its efforts in the health sector are no exception. By leveraging advanced artificial intelligence (AI) capabilities, the tech giant aims to enhance global health outcomes through improved accessibility to quality health
GRObio, a spinout from the George Church Lab at Harvard University, has encountered significant hurdles lately. Founded in 2016, GRObio focuses on developing therapeutic proteins built on nonstandard amino acids (NSAAs). Despite its pioneering approach, the company is undergoing a period of
Immunovant, a biotechnology company known for its innovative treatments for autoimmune diseases, has recently announced a significant shift in its development strategy. Despite late-stage successes with its experimental drug batoclimab, the company has decided to momentarily hold back on seeking
